Pre- vaccination seroprevalence of rubella IgM among women of child bearing age in southeast Nigeria: a five-year cross-sectional study.

Authors

Chinedu Michael Chukwubike, Chioma Uju Benjamin-Puja, Constance Ugochi Azubuike, Chioma Chinyere Edu-Alamba, Elezuo Okorie Elezuo, Chuma Emembolu, Ogbonna Nwabeke, Okechukwu Ogbodo, Hyacinth Egbuna, Princess Ada Ojeanyah, Jennifer Ifeoma Ajaegbu, Chinenye Ibeh, Oluchi Obioma Adighogu, Chika David Okudoh, Roseline Adolphus-Chukwuemeka, Leonard Ihedioha, Abudullahi Salihu, Blessing Ekanem, Martin Chukwuji, Olajumoke Babatunde, Mary Indyeriyo-Kaan Dooshima

Published in

Japanese journal of infectious diseases. Jun 30, 2026. Epub Jun 30, 2026.

Abstract

Rubella is an acute, contagious viral illness that is generally mild, yet infection during early pregnancy can cause congenital rubella syndrome (CRS), a serious condition associated with deafness, blindness, congenital heart defects, and developmental disabilities. Although vaccination is the only effective preventive measure, rubella continues to circulate in regions with low immunization coverage. This study assessed the pre-vaccination seroprevalence of rubella IgM antibodies among women of reproductive age in Southeast Nigeria. A retrospective cross-sectional study was conducted from 2020 to 2024 among 405 women aged 15-49 years across five states in Southeast Nigeria. Serum samples were tested for rubella IgM antibodies using ELISA. Rubella IgM seroprevalence was 6.7% (27/405). Adolescents, 15-19 years had the highest positivity (11.7%), with prevalence declining steadily with age to 1.9% among women aged 30-34 years. Rubella positivity peaked in 2020 (16.0%) and 2024 (14.5%), with Imo State showing the highest prevalence (10.1%) and an incidence of 7.3 per 1,000,000 population. Rubella IgM positivity among women of childbearing age indicates ongoing transmission and susceptibility, particularly among adolescents. These findings provide baseline data for assessing vaccine impact and highlight the need for stronger surveillance and improved uptake to prevent CRS in Nigeria.

PMID:
42386596
Bibliographic data and abstract were imported from PubMed on 02 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.